Хирургическое и комбинированное лечение карциносаркомы матки


Е.В. Бахидзе (1, 3), А.В. Беляева (1, 2)

1) ФГБУ «НИМЦ онкологии им. Н.Н. Петрова» Минздрава России, Санкт-Петербург; 2) ГБУЗ «Санкт-Петербургский клинический научно-практический центр специализированных видов медицинской помощи (онкологический)», Санкт-Петербург; 3) ФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И. Мечникова» МЗ РФ, Санкт-Петербург
В ретроспективном нерандомизированном исследовании проанализированы результаты лечения 28 больных карциносаркомой матки (КСМ), госпитализированных в онкогинекологическое отделение НИМЦ онкологии им. Н.Н. Петрова с 2004 по 2014 г. Отсутствие стандартов лечения КСМ обусловлено сложностью проведения проспективных рандомизированных исследований в связи с редкостью заболевания, являющегося высокоагрессивной злокачественной опухолью. Общая 5-летняя выживаемость больных КСМ I–III стадий достаточно низкая – около 50%, а безрецидивная – около 30%. Оптимальное хирургическое стадирование, подразумевающее выполнение тазовой лимфодиссекции, и применение адъювантной лучевой терапии больных КСМ позволяют добиться снижения частоты рецидивов. Проведение дальнейших рандомизированных исследований будет способствовать стандартизации подходов к хирургическому и комбинированному лечению КСМ.

Литература


1. Bansal N., Herzog T.J., Seshan V.E., Schiff P.B., Burke W.M., Cohen C.J., Wright J.D. Uterine carcinosarcomas and grade 3 endometrioid cancers: evidence for distinct tumor behavior. Obstet. Gynecol. 2008;112:64–70.

2. Berton-Rigaud D., Devouassoux-Shisheboran M., Ledermann J.A., et al. Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma. Int. J. Gynecol. Cancer. 2014;24(9 Suppl 3):S55–60.

3. Tavassoli F.A., Devilee P., еds. World Health Organization classification of tumours. In: Pathology and genetics of tumours of the breast and female genital organs. Lyon, 2003.

4. Silverberg S.G., Major F.J., Blessing J.A., Fetter B., Askin F.B., Liao S.Y., Miller A. Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. A Gynecologic Oncology Group pathologic study of 203 cases. Int. J. Gynecol. Pathol. 1990;9:1–19.

5. Disaia P.J., Creasman W.T. Sarcoma of the uterus. In: D isaia P.J., Creasman W.T., eds. Clinical gynecologic oncology. St. Louis, 2002.

6. Arend R., Doneza J.A., Wright J.D. Uterine carcinosarcoma. Curr. Opin. Oncol. 2011;23:531–36.

7. Kanthan R., Senger J.L. Uterine carcinosarcomas (malignant mixed mullerian tumors): a review with special emphasis on the controversies in management. Obstet. Gynecol. Int. 2011;2011:470795.

8. McCluggage W.G. Malignant biphasic uterine tumors: carcinosarcomas or metaplastic carcinomas? J. Clin. Pathol. 2002;55:321–25.

9. D’Angelo E., Prat J. Pathology of mixed Mullerian tumors. Best Pract. Res. Clin. Obstet. Gynecol. 2011;25:705–18.

10. Semczuk A., Ignatov A., Obrzut B., Reventos J., Rechberger T. Role of p53 pathway alterations in uterine carcinosarcomas (Malignant Mixed Mullerian Tumors). Oncology. 2014;87:193–204.

11. Gorai I., Yanagibashi T., Taki A., Udagawa K., Miyagi E., Nakazawa T., Hirahara F., Nagashima Y., Minaguchi H.Uterine carcinosarcoma is derived from a single stem cell: an in vitro study. Int. J. Cancer. 1997;72:821–27.

12. Huang G.S., Gunter M.J., Arend R.C., Li M., Arias-Pulido H., Prossnitz E.R., Goldberg G.L., Smith H.O. Co-expression of GPR30 and ERβ and their association with disease progression in uterine carcinosarcoma. Am. J. Obstet. Gynecol. 2010;203(3):242.e1–42.

13. Yildirim Y., Inal M.M., Sanci M., Yildirim Y.K., Mit T., Polat M., Tinar S. Development of uterine sarcoma after tamoxifen treatment for breast cancer: report of four cases. Int. J. Gynecol. Cancer. 2005;15:1239–42.

14. Arenas M., Rovirosa A., Hernandez V., Ordi J., Jorcano S., Mellado B., Biete A. Uterine sarcomas in breast cancer patients treated with tamoxifen. Int. J. Gynecol. Cancer. 2006;16:861–65.

15. Tseng C.E., Chen C.H., Chen S.J., Chi C.L. Tumor rupture as an initial manifestation of malignant mesonephric mixed tumor: a case report and review of the literature. Int. J. Clin. Exp. Pathol. 2014;7(3):1212–17.

16. Lu C.H., Chen I.H., Chen Y.J., Wang K.L., Qiu J.T., Lin H., Lin W.C., Liou W.S., Huang Y.F., Lin Y.S., Tee Y.T., Hung Y.C. Primary treatment and prognostic factors of carcinosarcoma of the ovary, fallopian tube, and peritoneum: a Taiwanese Gynecologic Oncology Group Study. Int. J. Gynecol. Cancer. 2014;24(3):506–12.

17. Dave K.S., Chauhan A., Bhansali R., Arora R., Purohit S. Uterine carcinosarcomas: 8-year single center experience of 25 cases. Indian J. Med. Paediatr. Oncol. 2011;32(3):149–53.

18. Benoit L., Arnould L., Cheynel N., et al. The role of surgery and treatment trends in uterine sarcoma. Eur. J. Surg. Oncol. 2005;31:434–42.

19. Sorbe B., Paulsson G., Andersson S.. Steineck G. A population-based series of uterine carcinosarcomas with long-term follow-up. Acta Oncologica. 2013;52:759–66.

20. Chiyoda T., Tsuda H., Tanaka H., et al. K Expression profiles of carcinosarcomas of the uterine corpus – are these similar to carcinoma or sarcoma? Genes Chromosomes Cancer. 2012;51:229–39.

21. Bendifallah S., Canlorbe G., Raimond E., et al. A clue towards improving the European Society of Medical Oncology risk group classification in apparent early stage endometrial cancer? Impact of lymphovascular space invasion. Br. J. Cancer. 2014;110:2640–46.

22. Colombo N., Creutzberg C., Amant F., Bosse T., González-Martín A., Ledermann J., Marth C., Nout R., Querleu D., Mirza M.R., Sessa C. ESMO-ESGO-ESTRO Consensus Conferenc on Endometrial Cancer: diagnosis, treatment and follow-up. Annals Oncol. 2016;27:16–41.

23. Nout R.A., Smit V.T., Putter H., Jürgenliemk-Schulz I.M., Jobsen J.J., Lutgens L.C., van der Steen-Banasik E.M., Mens J.W., Slot A., Kroese M.C., van Bunningen B.N., Ansink A.C., van Putten W.L., Creutzberg C.L. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet. 2010;375:816–23.

24. Sorbe B., Horvath G., Andersson H., Boman K., Lundgren C., Pettersson B. External pelvic and vaginal irradiation versus vaginal irradiation alone as postoperative therapy in medium-riskendometrial carcinoma – a prospective randomized study. Int J. Radiat. Oncol. BiolPhys. 2012;82:1249–55.

25. McMeekin D.S., Filiaci V.L., Aghajanian C., et al. A randomized phase III trial of pelvic radiation therapy (PXRT) versus vaginal cuff brachytherapy followed by paclitaxel/ carboplatin chemotherapy (VCB/C) in patients with high risk (HR), early stage endometrial cancer (EC): a Gynecologic Oncology Group trial. Gynecol Oncol 2014;134:438 (abstract LBA 431).

26. Chi D.S., Mychalczak B., Saigo P.E., Rescigno J., Brown C.L. The role of whole-pelvic irradiation in the treatment of early-stage uterine carcinosarcomas. Gynecol. Oncol. 1997;65:493–98.

27. Reed N.S., Mangioni C., Malmström H., Scarfone G., Poveda A., Pecorelli S., et al. European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur. J. Cancer. 2008;44:808–18.

28. Livi L., Paiar F., Shah N., Blake P., Villanucci A., Amunni G., Barca R., Judson I., Lodge N., Meldolesi E., Simontacchi G., Piperno G., Galardi A., Scoccianti S., Biti G.P., Harmer C. Uterine sarcoma: Twenty-seven years of experience. Int. J. Radiat. Oncol. Biol. Phys. 2003;57:1366–73.

29. Brooks S.E., Zhan M., Cote T., Baquet C.R. Surveillance, epidemiology, and end esults analysis of 2677 cases of uterine sarcoma 1989–1999. Gynecol. Oncol. 2004;93:204–8.

30. Cha J., Kim Y.S., Park W., et al. Clinical significance of radiotherapy in patients with primary uterine carcinosarcoma: a multicenter retrospective study (KROG 13-08). J Gynecol Oncol. 2016;27(6):e58.

31. Greven K., Winter K., Underhill K., Fontenesci J., Cooper J., Burke T. Final analysis of RTOG 9708: adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer. Gynecol. Oncol. 2006;103:155–59.

32. De Boer S.M., Powell M.E., Mileshkin L., et al. Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncology. 2016;17:1114–26.

33. Wolfson A.H., Brady M.F., Rocereto T., Mannel R.S., Lee Y.C., Futoran R.J., Cohn D.E., Ioffe O.B. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs .cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcomas (CS) of the uterus. Gynecol. Oncol. 2007;107:177–85.

34. Dandamudi R.K., Aaslam S., Walji N., El-Modir A., Fernando I.Hemotherapy for Uterine Carcinosarcoma with Carboplatin, Ifosfamide and Mesna. Anticancer Res. 2015;35:4841–48.

35. Menczer J., Levy T., Piura B., Chetrit A., Altaras M., Meirovitz M., Glezerman M., Fishman A. A comparison between different postoperative modalities of uterine carcinosarcomas. Gynecol. Oncol. 2005;97:166–70.

36. Makker V., Abu-Rustum N.R., Alektiar K.M., Aghajanian C.A., Zhou Q., Iasonos A., Hensley M.L. A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for ompletely resected stage I–IV uterine carcinosarcomas. Gynecol. Oncol. 2008;111:249–54.

37. Einstein M.H., Klobocista M., Hou J.Y., Lee S., Mutyala S., Mehta K., Reimers L.L., Kuo D.Y.S., Huang G.S., Goldberg G.L. Phase II trial of adjuvant pelvic radiation «sandwiched» between ifosfamide or ifosfamide plus cisplatin in women with uterine carcinosarcoma . Gynecol Oncol 2012;124:26–30.

38. Glasgow M., Vogel R.I., Burgart J., Argenta P., Dusenbery K., Geller M. ALong term follow-up of a phase II trial of multimodal therapy given in a “sandwich” method for stage III, IV, and recurrent endometrial cancer. Gynecol. Oncol. Res. Pract. 2016;3:6.


Об авторах / Для корреспонденции


Автор для связи: Е.В. Бахидзе – д.м.н., ведущий науч. сотр. научного отделения онкогинекологии ФГБУ «НИМЦ онкологии им. Н.Н. Петрова» Минздрава России, доцент кафедры акушерства и гинекологии ФГБОУ ВО СЗГМУ им. И.И. Мечникова МЗ РФ, Санкт-Петербург; e-mail: bakhidze@yandex.ru


Бионика Медиа